As GLP-1 drugs like Ozempic and Zepbound surge in popularity, some patients and doctors report a side effect of emotional flattening, colloquially termed 'Ozempic personality' or anhedonia. While large-scale studies in The Lancet and the BMJ link these medications to improved mental health outcomes and reduced substance abuse, researchers like Daniel Drucker and Zak Krumm are investigating how GLP-1s might blunt dopamine reward pathways. Many clinical cases of emotional blunting appear to resolve successfully after patients reduce their medication dosage.
Emotional blunting reports
- ▪Eli Lilly stated that the company does not have data to share regarding anhedonia associated with its GLP-1 medications
- ▪Novo Nordisk spokesperson Liz Skrbkova stated that anhedonia is not currently listed as an adverse drug reaction or warning for the company's GLP-1 medications
- ▪Doctors and patients report experiencing emotional flattening, colloquially termed 'Ozempic personality' or anhedonia, while taking GLP-1 receptor agonist medications.
Dopamine reward system effects
- ▪Obesity researcher Daniel Drucker suggests GLP-1 medications may tone down brain regions associated with pleasure, potentially blunting reward pathways at extreme dosages
- ▪University of Florida researcher Zak Krumm conducted rat experiments suggesting that GLP-1 drugs chronically mute dopamine responses to high-value rewards
- ▪Animal experiments conducted in Michigan suggest GLP-1 drugs may accelerate dopamine satisfaction signals, leading to a quicker sense of reward satisfaction
Clinical case observations
- ▪Spencer Nadolsky and Zak Krumm are compiling case studies of approximately 100 patients to characterize the emotional blunting phenomenon associated with GLP-1 drugs
- ▪Registered dietitian Summer Kessel observed clients on GLP-1 medications reporting lack of motivation and gravitating toward intensely flavored foods like sour gummy candies
Dosage adjustment outcomes
- ▪Patient Korrie Stevenson reported that reducing her weekly Zepbound dose from 15 milligrams to 12.5 milligrams resolved her emotional apathy within two weeks
- ▪University of Florida researcher Zak Krumm noted that most cases of GLP-1-induced emotional blunting resolve within weeks when the medication dosage is reduced
GLP-1 mental health research
- ▪An April 2026 study in The Lancet involving 95,000 people linked semaglutide to a lower risk of worsening depression, anxiety, and self-harm
- ▪A March 2026 study in the BMJ analyzing data from 606,000 people associated GLP-1 drugs with fewer substance-related deaths and overdoses
Story comments
Loading comments…